Australia's Patrys jumps as study validates potential of antibody

Patrys

14/03/2023 01:04

** Shares of Patrys Ltd  PAB.AX  jump as much as 12.5% to
A$0.027 - set to mark best day since Jan 6, if current gains
hold 
    ** Therapeutic antibody maker says pre-clinical study
results validate potential to use its full size IgG deoxymab,
PATDX3, for synthetic lethality strategies to treat relevant
cancers
    ** Says in a pre-clinical colon cancer study in mice treated
with PAT-DX3, tumours with a compromised DNA Damage Response
systems showed a 71% reduction in growth
    ** Stock hits highest level since March 7
    ** More than 2.9 mln shares change hands, vs the 30-day
average volume of 2.8 mln shares
    ** Stock down 11.1% this year, as of last close

 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))